No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
102 |
4. Check minimum number of eventsNone |
102 |
5. Include endpointsNone |
102 |
6. Filter based on genotype QC (FinnGen only) |
90 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L44
- Name in latin
- Pityriasis rubra pilaris
Similar endpoints
↥List of similar endpoints to
Pityriasis rubra pilaris
based on the number of shared cases.
Similar with more cases:
- Other papulosquamous disorders
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 659 | 274 | 382 |
| Only index persons | 598 | 256 | 342 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.03 | 55.27 | 53.05 |
| Only index persons | 53.38 | 55.70 | 51.65 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 90 | 45 | 45 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 59.05 | 52.06 | 66.03 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 94
- Matched controls
- 940
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
+∞
120.4
88
*
D05BB02
ATC
acitretin; oral
+∞
54.6
47
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
20.9
45.1
42
35
D07XC01
ATC
betamethasone; topical
15.4
34.5
37
38
D07AC01
ATC
betamethasone; topical
10.4
27.3
69
197
L30.9
ICD-10 Finland
Dermatitis, unspecified
9.1
26.4
52
113
L04AX03
ATC
methotrexate; systemic
11.6
25.6
32
40
E0000UV, ,
ATC
10.9
24.9
75
250
D07AD01
ATC
clobetasol; topical
9.3
23.9
38
64
L40.0
ICD-10 Finland
Psoriasis vulgaris
300.2
23.8
23
*
D07AC13
ATC
mometasone; topical
7.1
20.8
53
144
D07AB08
ATC
desonide; topical
7.4
17.5
32
61
D07AB02
ATC
hydrocortisone butyrate; topical
5.3
14.6
51
173
E000001, ,
ATC
5.5
14.2
39
108
D05AX52
ATC
calcipotriol, combinations; topical
22.6
14.1
20
11
L26
ICD-10 Finland
Exfoliative dermatitis
+∞
13.9
13
*
TQW80
NOMESCO Finland
Local dermatologic skincare
22.7
12.1
17
9
D02AE01
ATC
carbamide; topical
12.1
12.1
22
23
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.2
12.0
24
49
134
Kela drug reimbursment
General erythroderma
+∞
9.5
9
*
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
98.5
8.6
9
*
H02AB06
ATC
prednisolone; systemic
3.6
8.3
60
309
D05AX02
ATC
calcipotriol; topical
27.6
7.7
10
*
E000003, ,
ATC
9.7
7.7
15
18
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
4.8
7.2
18
44
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
79
453
5.66
10.16
15.6
10.8
4.52
4.16
e9/l
0.90
73
397
24
71
4.20
7.59
4.3
3.4
—
—
—
0
0
24
80
3.69
6.36
5.3
1.9
255.58
377.85
nmol/l
2.13
24
72
83
585
4.58
6.07
5.7
4.4
14.79
14.75
pmol/l
0.06
74
536
11
14
8.73
5.52
1.5
1.6
—
—
—
0
0
41
215
2.61
4.80
3.4
2.9
0.23
0.34
e6/l
0.31
32
161
38
192
2.64
4.80
2.1
2.1
3.09
2.74
mg/l
0.28
31
171
79
593
3.08
4.10
6.1
4.1
10.45
10.64
mm/h
0.05
74
553
36
190
2.45
4.04
1.4
1.3
1.00
1.50
u/ml
0.38
11
50
58
383
2.34
3.85
3.8
3.0
98.46
104.82
ug/l
0.16
47
362
56
367
2.30
3.75
7.9
6.9
1.19
1.21
mmol/l
0.67
48
324
86
720
3.28
3.23
7.7
5.2
1.84
1.90
mu/l
0.14
79
659
36
209
2.17
3.12
1.9
2.9
359.90
341.55
umol/l
0.41
30
181
6
8
7.91
3.10
2.3
1.3
—
—
—
0
0
81
650
2.78
3.07
28.6
17.8
13.76
13.57
%
0.45
81
645
5
5
10.45
3.01
1.0
1.0
—
—
—
0
0
13
48
2.98
2.85
11.4
10.1
1.21
1.16
mmol/l
0.08
13
48
49
336
1.96
2.60
1.7
2.0
83.92
95.16
pmol/l
0.83
26
190
6
11
5.74
2.58
2.8
1.8
16.72
16.87
%
—
6
11
48
335
1.88
2.35
2.7
1.8
1.56
1.31
mmol/l
1.56
40
269
86
751
2.70
2.26
5.6
5.0
5.97
5.88
mmol/l
0.27
77
698
26
149
2.03
2.25
1.8
1.7
394.89
424.17
pmol/l
0.23
19
132
37
244
1.85
2.11
4.3
3.5
0.00
0.00
estimate
-0.00
18
75
56
426
1.78
1.95
5.2
3.7
0.00
0.00
estimate
-0.00
19
84
8
28
3.03
1.91
2.0
1.5
—
—
—
0
0
87
776
2.62
1.90
23.6
14.8
19.84
24.17
mg/l
0.73
76
624
35
234
1.79
1.88
4.1
3.2
0.00
0.00
estimate
-0.00
17
60
56
430
1.75
1.85
5.3
3.8
0.00
0.00
estimate
-0.00
16
77
5
12
4.33
1.84
1.4
1.2
—
—
—
0
0
55
421
1.74
1.83
5.2
3.7
0.00
0.00
estimate
-0.00
19
81
12
54
2.40
1.83
1.6
1.5
—
—
—
0
0
84
734
2.36
1.82
6.3
4.2
1.48
1.26
mmol/l
1.80
76
681
7
24
3.07
1.76
1.0
1.1
—
—
—
0
0
7
24
3.07
1.76
1.0
1.1
—
—
—
0
0
42
301
1.71
1.75
4.1
3.5
61.53
27.06
ng/l
0.84
32
206
10
40
2.67
1.73
14.8
9.6
24.92
25.23
mmol/l
—
10
40
36
249
1.72
1.69
6.5
3.7
15.08
10.31
mg/mmol
0.29
25
168
6
19
3.30
1.69
1.2
1.4
—
—
—
0
0
86
774
2.30
1.68
7.7
5.0
4.65
4.58
mmol/l
0.21
81
723
86
774
2.30
1.68
6.3
4.9
1.34
1.45
mmol/l
1.62
77
718
5
14
3.71
1.63
9.2
1.6
10.76
5.29
pmol/l
—
5
14
15
80
2.04
1.55
2.7
2.2
0.26
0.23
e6/l
0.06
15
75
33
229
1.68
1.51
1.3
1.7
15.95
19.71
nmol/l
0.98
28
196
9
39
2.44
1.48
3.7
1.5
40.56
40.15
u/l
—
9
32
82
729
1.98
1.39
7.5
6.2
39.35
38.66
mmol/mol
0.28
75
687
23
148
1.73
1.37
1.7
1.3
1.18
6.03
u/ml
—
9
52
6
24
2.60
1.32
1.0
1.3
—
—
—
0
0
5
18
2.87
1.30
1.2
1.3
—
—
—
0
0
86
786
2.10
1.28
7.6
5.6
2.76
2.69
mmol/l
0.28
77
735
20
127
1.73
1.24
2.4
2.6
0.89
0.77
e6/l
0.10
11
74
5
19
2.72
1.23
2.2
1.4
—
—
—
0
0
5
20
2.58
1.16
1.0
1.6
—
—
—
0
0
18
115
1.70
1.09
3.0
2.7
0.62
2.33
e6/l
—
9
63
42
330
1.49
1.08
5.7
3.7
0.00
0.00
estimate
-0.00
17
66
7
129
0.51
0.97
3.1
1.5
—
—
—
0
0
24
174
1.51
0.88
2.8
2.3
—
—
—
0
0
62
542
1.42
0.83
3.4
3.2
60.64
45.89
u/l
0.87
56
516
6
34
1.82
0.77
5.8
2.6
1.05
1.25
%
—
6
34
5
23
2.24
0.77
2.6
1.5
—
—
—
0
0
5
23
2.24
0.77
1.0
1.7
—
—
—
0
0
7
41
1.76
0.71
1.0
1.3
—
—
—
0
0
6
105
0.54
0.66
1.7
2.1
—
—
—
0
0
5
29
1.76
0.64
1.6
1.2
—
—
—
0
0
42
358
1.31
0.60
2.8
2.7
—
—
estimate
—
0
0
0
23
0.00
0.59
0.0
1.6
—
0.90
—
0
13
0
23
0.00
0.59
0.0
1.6
—
1.20
—
0
13
0
23
0.00
0.59
0.0
1.9
—
62.48
—
0
18
0
23
0.00
0.59
0.0
1.5
—
—
—
0
0
0
23
0.00
0.59
0.0
1.6
—
1.15
—
0
13
6
35
1.76
0.59
1.2
1.0
—
—
—
0
0
13
91
1.50
0.56
1.5
1.9
—
—
—
0
0
6
38
1.62
0.55
2.2
1.7
—
—
—
0
0
6
100
0.57
0.55
1.7
1.9
—
—
—
0
0
7
49
1.46
0.47
4.0
2.9
4.88
4.93
kpa
—
7
49
13
97
1.39
0.42
1.5
1.8
—
—
—
0
0
16
124
1.35
0.42
2.2
2.0
—
—
—
0
0
5
33
1.54
0.42
1.2
1.2
—
2.74
—
0
7
0
15
0.00
0.41
0.0
1.8
—
2.35
—
0
15
0
17
0.00
0.41
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.5
—
50.25
—
0
18
5
35
1.45
0.40
1.2
1.2
—
—
—
0
0
5
36
1.41
0.39
1.6
1.3
—
—
—
0
0
5
36
1.41
0.39
4.8
3.7
24.18
24.31
mmol/l
—
5
36
22
183
1.26
0.36
5.7
3.8
1.02
1.02
kg/l
0.99
13
126
6
89
0.65
0.34
3.0
6.7
—
—
—
0
0
20
167
1.25
0.32
1.6
1.3
10.94
36.01
iu/ml
—
5
50
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
0.82
—
0
6
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
54
511
1.13
0.19
2.7
3.2
—
—
—
0
0
18
202
0.87
0.16
5.1
3.2
0.55
0.70
ug/l
0.76
13
138
24
263
0.88
0.15
6.0
4.6
20.88
21.40
%
0.05
12
133
6
73
0.81
0.08
1.3
1.4
—
—
—
0
0
14
143
0.98
0.00
1.4
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
6.64
—
0
9
5
54
0.92
-0.00
2.2
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
1.14
—
0
7
0
8
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.0
—
6.93
—
0
9
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
12.73
—
0
6
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.1
—
1.13
—
0
8
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
12.83
—
0
6
0
6
0.00
-0.00
0.0
2.7
—
58.00
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint L12_PITYRIASISRUBRA and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have L12_PITYRIASISRUBRA.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: L12_PITYRIASISRUBRA – Pityriasis rubra pilaris
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data